Is SPRO stock a Buy, Sell, or Hold?

Based on our analysis, SPRO is currently a HOLD with low confidence. 📊 HOLD: SPRO shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.

What is the fair value of SPRO stock?

Our analysis estimates the fair value range for SPRO to be between $2.28 and $2.50. The current price is $2.23.

What is the analyst price target for SPRO?

The average Wall Street analyst price target for SPRO is $4.00. This implies a potential upside of 79.4% from current levels.

SPRO Stock Analysis: Buy, Sell, or Hold?

SPRO - Spero Therapeutics, Inc. Common Stock

PHARMACEUTICAL PREPARATIONS

$2.23

0.04 (1.83%) ▲

5d: -8.98%

30d: -4.29%

90d: -5.51%

HOLD

LOW Confidence

Last Updated: February 2, 2026

Earnings: Mar 26, 2026

Get Alerted When SPRO Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.

100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading historical data...

💡

Bottom Line:
📊 HOLD: SPRO shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

Adjust Growth Assumption: 10.0%

0% (Stagnation) 50% (Hyper Growth)

EST. PRICE IN 2031

$17.37

Based on 7.0% avg growth

INTRINSIC VALUE TODAY

$10.78

79.3% Margin of Safety

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 18.5x Exit PE.

View Full DCF Model

In-depth Analysis How we analyze

Valuation Analysis: SPRO is currently trading at $2.23, which is considered oversold relative to its 30-day fair value range of $2.28 to $2.50. From a valuation perspective, the stock is trading at a discount (Forward PE: 3.3) compared to its historical average (18.5). Remarkably, the market is currently pricing in an annual earnings decline of 43.5% over the next few years. This pessimistic expectation contrasts with the company's recent 75.3% earnings growth, suggesting potential undervaluation if the company simply maintains stability.

Technical Outlook: Technically, SPRO is in a uptrend. Immediate support is located at $2.14, while resistance sits at $2.46.

Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $4.00 (+79.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.

Quick Decision Summary

Current Position OVERSOLD

Fair Price Range $2.28 - $2.50

Company Quality Score 59/100 (HOLD)

Options IV Signal 50th percentile (NORMAL)

Volume Confirmation HIGH

Confidence Score 77.7%

All Signals

BULLISH: Price oversold vs 30-day range
NEUTRAL: Options fairly priced (IV 50th percentile)
NEUTRAL: Mixed technical signals (40/100)
BULLISH: High volume confirmation
BULLISH: Trading 79.4% below Wall St target ($4.00)
CAUTION: Recommendation downgraded due to -9.0% 5-day decline

Fair Price Analysis

30-Day Fair Range $2.28 - $2.50

Current vs Fair Value OVERSOLD

Expected Move (7 Days) ±$0.26 (11.6%)

Support & Resistance Levels

Support Level $2.14

Resistance Level $2.47

Current Trend Uptrend

Fundamental Context

Forward P/E (Next Year Est.) 3.33

Wall Street Target $4.00 (+79.4%)

Revenue Growth (YoY) -59.6%

Earnings Growth (YoY) 75.3%

Profit Margin -108.1%

Valuation Discount vs History -43.5% cheaper

PE vs Historical 3.3 vs 18.5 CHEAP

Market-Implied Price Targets If current PE multiple persists

Implied Growth (YoY): -43.5% (market-implied from PE analysis)

1-Year Target $2.01 (-10%)

2-Year Target $1.81 (-19%)

3-Year Target $1.63 (-27%)

3-Yr Target (if PE normalizes) (PE: 3→19) $9.04 (+305%)

💡 Upside Surprise Potential

If earnings stabilize (0% growth), PE could expand from 3.3 to 18.5

Stabilization Target: $12.40 (+455.8%)

PE Expansion Potential: +455.8%

Last updated: February 03, 2026 7:22 AM ET
Data refreshes hourly during market hours. Next update: 8:22 AM

🔥 Top Stocks Breaking Out Now

Ticker	Score	Recommendation	Change %

See Full Scanner Results »

Technical Signals Check

Is SPRO showing a specific setup today?

RSI Divergence Check TTM Squeeze Check MACD Crossover Check

Insider Activity (6 Months)

Buys

Sells

Net

INSIDERS SELLING

Recent Transactions

Ankit Mahadevia SELL 6572 shares 2025-08-28

View Insider Activity Scanner

Top Rated Biotechnology Stocks

Top-rated stocks in Biotechnology by analyst ratings.

Stock	Analyst Consensus	Analyst Target	Tradestie Score
BMRN Biomarin Pharmaceutical …	STRONG BUY 29 analysts	$91	61 BUY
CRSP Crispr Therapeutics AG	BUY 28 analysts	$85	59 HOLD
KYMR Kymera Therapeutics Inc	STRONG BUY 20 analysts	$117	61 BUY
BNTX BioNTech SE	STRONG BUY 21 analysts	$140	52 HOLD
VRDN Viridian Therapeutics Inc	STRONG BUY 16 analysts	$42	65 BUY

BMRN Biomarin Pharmace…

61 BUY

CRSP Crispr Therapeuti…

59 HOLD

KYMR Kymera Therapeuti…

61 BUY

BNTX BioNTech SE

52 HOLD

VRDN Viridian Therapeu…

65 BUY

More Analysis for SPRO

SPRO Technical Chart SPRO Price Prediction SPRO Earnings Date SPRO Investment Advisor SPRO Fair Price Analyzer SPRO Competitors

Compare SPRO with Other Stocks

Create New Comparison

Tradestie